Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02086786 · ClinicalTrials.gov registry record · Phase 2
Pharmacokinetics and Tolerability Study of Risperidone ISM® in Schizophrenia
A Phase 2 study, sponsored by Rovi Pharmaceuticals Laboratories.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT02086786 is a Phase 2 study that has completed, run by Rovi Pharmaceuticals Laboratories. The registered enrollment target is 70 participants.
The verdict
NCT02086786, a Phase 2 study, has completed, sponsored by Rovi Pharmaceuticals Laboratories.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
To characterize the pharmacokinetics (PK) of the injectable intramuscular (IM) long-acting formulation (in situ microparticle, ISM) of risperidone over four IM injections in the gluteal and deltoid muscle at 28-day intervals and at one dose strength (75 mg) in patients with schizophrenia.
Interventions
- DRUG Risperidone ISM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2014-03 |
| Est. Completion | 2015-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02086786
The ClinicalTrials.gov registry entry for NCT02086786 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rovi Pharmaceuticals Laboratories, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Risperidone ISM is the first listed.
NCT02086786 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02086786 about?
NCT02086786 is a clinical study titled "Pharmacokinetics and Tolerability Study of Risperidone ISM® in Schizophrenia". To characterize the pharmacokinetics (PK) of the injectable intramuscular (IM) long-acting formulation (in situ microparticle, ISM) of risperidone over four IM injections in the gluteal and deltoid muscle at 28-day intervals and at one dose strength (75 mg) in patients with schizophrenia.
What is the current status of trial NCT02086786?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2014-03. Estimated completion is 2015-03.
What interventions are being tested in trial NCT02086786?
The interventions under investigation include: Risperidone ISM (DRUG).
Who is sponsoring clinical trial NCT02086786?
This trial is sponsored by Rovi Pharmaceuticals Laboratories, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.